Botulinum Toxin in the Treatment of Raynaud's
Raynaud's Syndrome
About this trial
This is an interventional treatment trial for Raynaud's Syndrome focused on measuring Scleroderma, Raynaud's Syndrome
Eligibility Criteria
Inclusion Criteria:Adult (>18 years) patients with severe RP of any etiology will be invited to participate. Inclusion criteria include a) history of digital infarcts or ulcerations, b) unresponsive to standard therapies, or c) impending potential for digital amputation. Patients on other standard therapies such as antiplatelet agents, vasodilators, and calcium channel blockers will be included. -
Exclusion Criteria:Pregnancy, mild disease, patients with myasthenia gravis, botulinum toxin allergy, and phobia of needles are exclusion criteria. Women of childbearing age will need to demonstrate a negative urine pregnancy test. Myasthenia gravis is excluded because underlying generalized weakness can be exacerbated, and local weakness at injection sites can occur more than otherwise expected.
-
Sites / Locations
- Emory University
Arms of the Study
Arm 1
Placebo Comparator
Botox
single-drug dosage comparison cross-over study